Chicago Lymphoma Symposium 2022 Abstracts


PDF File

Utility Estimation of Rituximab Versus Bendamustine-Rituximab Induction in Indolent Non-Hodgkin Lymphomas Using Patient-Reported Quality of Life Survey Data

Impact of cachexia at apheresis and infusion on post-CAR-T cell therapy outcomes in aggressive lymphoma
End of Treatment peripheral blood TCR evaluation for minimal residual disease evaluation in Peripheral T-cell Lymphomas
Pre-anthracycline left ventricular ejection fraction (LVEF) assessment and long-term cardiovascular (CV) outcomes in adolescent & young adult (AYA) lymphoma survivors
Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma
Phase 1/2 Trial of Bispecific LV20.19 CAR T-cells for Relapsed, Refractory (R/R) Mantle Cell Lymphoma
Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era: A follow-up analysi
A Case of Angioimmunoblastic Lymphoma Presenting as Airway Obstruction
Renal Tubulopathy associated with Cytokine Release Syndrome after CD-19 CAR T Cell therapy in a patient with refractory DLBCL
Alliance A059102: A Randomized Phase II US Intergroup Study of CHO(E)P VS CC-486-CHO(E)P VS DUVELISIB-CHO(E)P in Previously Untreated CD30 Negatrive Perhpheral T-cell Lymphomas (PTCL)
A multicenter, single-arm, phase I/II dose finding and efficacy study of venetoclax, CC-486, and obinutuzumab in minimally-pretreated follicular lymphoma

ABSTRACTS CLOSE: March 25, 2022

Abstract Submission Guidelines

Word count: 700 (inclusive of title and abstract text) Font: Arial; Font Size: 11 The suggested structure is outlined below; however, it is not required: Introduction, Methods, Results, Conclusions
  • Multiple paragraphs are permitted.
  • Do not use bold or underline formatting; italics are permitted.
  • Use numerals to indicate numbers unless they are at the beginning of a sentence.
  • References are to be cited within the text, not as footnotes.
  • Figures and tables are not included in the text count and must be uploaded as separate files. See below for file guidelines.
  • Please ensure any symbols are viewable and accurate after entering your abstract.
  • The title should objectively describe the study.
  • The title Should be in sentence case.
  • Please use generic names rather than proprietary drug names.
  • Keep in mind, the title should not allude to a result or conclusion of the study.
Abstract type
  • All types of clinic-based and laboratory-based research projects relating lymphoma are eligible for submission.     
    • If a clinical trial, indicate if the trial has been registered, the registry, and the registration number.
  • Figures and Tables
    • Figures and tables must be submitted as images and thus do not count towards the character count limit.
    • Files should be shared as jpeg, png, or gif. PDF and TIF files are NOT permitted.

Abstract Submission Guidelines

Abstracts should be submitted to by Friday, March 25, 2022.

Please direct any questions regarding abstracts to